PDCD1 and neoplasm: The mechanism for this phenomenon may be that the characteristic tumor micro-environment of BLI is more suitable for PD-1/PD-L1 pathway inhibitors to work, thereby reversing T lymphocyte exhaustion in tumor tissues, restoring T lymphocyte activity, and better exerting anti-tumor effects.